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Summary Purpose Ixazomib is an investigational protea-
some inhibitor with demonstrated antitumor activity in xeno-
graft models of multiple myeloma (MM), lymphoma, and
solid tumors. This open-label, phase 1 study investigated in-
travenous (IV) ixazomib, in adult patients with advanced non-
hematologic malignancies. Methods Patients received IV
ixazomib twice-weekly for up to twelve 21-day cycles. The
0.125 mg/m2 starting dose was doubled (one patient/dose)
until 1.0 mg/m2 based on dose-limiting toxicities (DLTs) in
cycle 1. This was followed by 3+3 dose-escalation and ex-
pansion at the maximum tolerated dose (MTD). Primary ob-
jectives included safety and MTD assessment. Secondary ob-
jectives included assessment of pharmacokinetics, pharmaco-
dynamics, and disease response. Results Ixazomib was esca-
lated from 0.125 to 2.34 mg/m2 to determine the MTD (n=
23); patients were then enrolled to MTD expansion (n=73)
and pharmacodynamic (n=20) cohorts. Five patients experi-
enced DLTs (1.0 and 1.76 mg/m2: grade 3 pruritic rash;
2.34 mg/m2: grade 3 and 4 thrombocytopenia, and grade 3
acute renal failure); thus, the MTD was 1.76 mg/m2. Drug-
related grade ≥3 adverse events (AEs) included thrombocyto-
penia (23 %), skin and subcutaneous (SC) tissue disorders
(16 %), and fatigue (9 %). Among 92 evaluable patients,
one (head and neck cancer) had a partial response and
30 had stable disease. Ixazomib terminal half-life was
3.8–7.2 days; plasma exposures increased dose-
proportionally and drug was distributed to tumors. Inhi-
bition of whole-blood 20S proteasome activity and up-
regulation of ATF-3 in tumor biopsies demonstrated tar-
get engagement. Conclusions In patients with solid tu-
mors, ixazomib was associated with a manageable safety
profile, limited antitumor activity, and evidence of
downstream proteasome inhibition effects.
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Introduction
The ubiquitin-proteasome system is a key pathway for protein
degradation and as such plays a key role in protein homeosta-
sis [1, 2]. Clinically, bortezomib has shown proteasome inhi-
bition to be a highly promising treatment strategy for multiple
myeloma (MM) and other hematologic malignancies [3–6].
Despite the proven efficacy in hematologic malignancies,
clinical activity is limited in solid tumors [7–13]. Preclinical
data; however, implied the potential for antitumor effects in
solid tumor models [14–18]. It has been suggested that a lack
of drug penetration into the tumor may be the cause of this
modest antitumor activity [19, 20].
The investigational agent ixazomib is an orally bioavail-
able, small molecule, potent, reversible, and selective inhibitor
of the β5 site of the 20S proteasome, which is structurally
different from bortezomib [20]. Ixazomib is currently being
investigated in phase 3 trials in MM (Clinicaltrials.gov iden-
tifiers NCT01564537 and NCT01850524) and primary sys-
temic AL amyloidosis (NCT01659658). When compared
with bortezomib, ixazomib demonstrated faster dissociation
from the proteasome in vitro, and data from mouse xenograft
models of human cancers suggested increased proteasome
inhibition in tumor tissue [20]. Preclinical studies also dem-
onstrated the antiproliferative activity of ixazomib in tumor
cell lines with potent antitumor activity in xenograft models
of MM, lymphoma, and some solid tumors [20–22]. These
data provided the rationale for the clinical development of
ixazomib in both hematologic and non-hematologic malig-
nancies. In clinical trials conducted to date, ixazomib was
studied as an intravenous (IV) formulation, initially, and sub-
sequently as an oral formulation.
This paper reports the results of the first-in-human, phase 1
dose-escalation study (NCT00830869) of twice-weekly IV
ixazomib in patients with advanced solid tumors. The study
included a drug distribution and pharmacodynamic assess-
ment of activating transcription factor-3 (ATF-3) levels in sol-
id tumor tissue as a marker of target engagement and an eval-
uation of whole blood 20S proteasome activity.
Materials and methods
Patients
Eligible participants were aged ≥18 years with a diagnosis of a
non-hematologic malignancy for which standard treatment
was no longer effective or did not offer curative or life-
prolonging potential. Eastern Cooperative Oncology Group
(ECOG) performance status of 0–2, absolute neutrophil count
(ANC) ≥1,500/mm3, platelet count ≥100,000/mm3, total bili-
rubin ≤1.5×the upper limit of normal (ULN), alanine amino-
transferase (ALT) and aspartate aminotransferase (AST)
≤2.5×ULN (≤5×ULN if the elevation can be reasonably as-
cribed tometastatic disease), creatinine clearance or calculated
creatinine clearance ≥60 mL/min, and QTc <470 ms on 12-
lead electrocardiogram were required. Patients also had no:
peripheral neuropathy (PN) of grade ≥2; diarrhea of grade
>1; recent (<14 days) major surgery; infection requiring sys-
temic antibiotic therapy; symptomatic brain metastasis; un-
controlled cardiovascular conditions within the past 6 months;
radiotherapy or systemic antineoplastic therapy within
21 days; or any investigational products within 28 days before
the first dose. In the disease-specific expansion and tumor
pharmacodynamic expansion (TPEC) cohorts, radiographi-
cally or clinically evaluable tumor (clinically measurable dis-
ease per Response Evaluation Criteria in Solid Tumors
[RECIST]) was required. An elevated prostate specific anti-
gen (PSA) level alone per modified Prostate Cancer Working
Group 2 (PCWG2) criteria was acceptable for evaluation of
prostate cancer.
All patients provided written informed consent and were
free to withdraw at any time during the study. Institutional
Review Boards at all participating institutions approved the
study and the informed consent documents. The study was
conducted according to the provisions of the Declaration of
Helsinki, the International Conference on Harmonization, and
Guidelines for Good Clinical Practice.
Study design
This open-label, non-randomized, dose-escalation phase 1
study was conducted at 7 sites in the United States and Can-
ada, with patients enrolled from March 02, 2009 to January
10, 2012. The primary objective of the trial was to determine
the safety profile, establish the maximum tolerated dose
(MTD), and inform the recommended phase 2 dose of IV
ixazomib in patients with non-hematologicmalignancies. Sec-
ondary objectives were to characterize the pharmacokinetics
and pharmacodynamics of IV ixazomib in blood and to eval-
uate disease response. Drug distribution and target engage-
ment in post-dose tumor samples was measured by determin-
ing the increase in ATF-3 levels in post-dose tumor samples
compared with pre-dose samples by immunohistochemistry
(IHC).
Patients received ixazomib as an IV bolus on days 1, 4, 8,
and 11 of a 21-day cycle, for up to 12 cycles, or until disease
progression or unacceptable toxicity. Patients who were
thought to potentially benefit from prolonged therapy could
receive continued treatment beyond 12 cycles according to the
treating physician’s consideration. Patients could receive pro-
phylactic antiviral therapy; prophylactic antidiarrheals and an-
tiemetics were not employed initially but could be considered
upon development of diarrhea or nausea/vomiting.
The dose-escalation cohort comprised patients with any
non-hematologic malignancy. The four MTD expansion
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cohorts were limited to patients with non-small cell lung can-
cer (NSCLC), head and neck cancer (squamous cell cancer),
soft tissue sarcoma, and prostate cancer, respectively. In addi-
tion, the TPEC was open to patients with non-hematologic
malignancy that could be safely biopsied. Dose escalation
initially proceeded from a starting dose of 0.125 mg/m2 of
body surface area, with one patient per dose level and dose
doubling up to a dose of 1.0 mg/m2. Dose doubling was per-
mitted until one of the following occurred: one patient expe-
rienced a dose-limiting toxicity (DLT) during cycle 1; any two
patients experienced a drug-related adverse event (AE) of
grade ≥2 during cycle 1; or the dose level of 1 mg/m2 had
been evaluated. Dose escalation then proceeded in 33 % in-
crements following a standard 3+3 schema based on the oc-
currence of DLTs in cycle 1. DLTs were defined as any of the
following: grade 4 neutropenia or thrombocytopenia lasting
for >7 consecutive days, or a platelet count of <10,000/mm3 at
any time; grade 3 neutropenia with infection/fever or throm-
bocytopenia with clinically significant bleeding; grade ≥3 PN;
grade 3 QTc prolongation; any other grade ≥3 non-
hematologic toxicity (despite optimal antiemetic prophylaxis
for nausea/emesis and supportive therapy for diarrhea), except
grade 3 arthralgia/myalgia or short-term (<1 week) grade 3
fatigue; a delay of >1 week in commencing cycle 2 due to
lack of adequate recovery of ixazomib-related toxicities; or
other grade ≥2 ixazomib-related toxicities requiring discontin-
uation in the opinion of the investigator. The MTD was de-
fined as the highest dose level at which 0/3 or 1/6 patients
experienced DLTs during cycle 1. Once the MTD had been
established, patients (including those from the dose-escalation
cohort meeting the eligibility criteria) were enrolled into four
MTD expansion cohorts and the TPEC, as defined above.
Assessments
AEs were monitored throughout the study and were graded
according to National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE) v3.0. Response
assessments were undertaken by investigators using a consis-
tent imaging modality in accordance with RECIST 1.0 [23] on
days 18–21 of cycle 2 and subsequent cycles. For patients
with prostate cancer, response and progressive disease were
based on RECIST for measurable neoplastic disease [23] or
on measurement of serum PSA per modified PCWG2 criteria
in the absence of measurable sites [24].
Blood samples for determination of plasma ixazomib con-
centrations for pharmacokinetic analysis (3 mL) and for mea-
surement of whole blood 20S proteasome activity (1 mL)
were collected at the following timepoints for all patients in
the dose-escalation cohort and for the first 12 patients com-
pleting cycle 1 while receiving protocol-specified treatment at
theMTD: pre-dose (within 1 h) on days 1, 4, 8, and 11 of cycle
1, and on day 1 of cycle 2; and on days 1 and 11, cycle 1, at 5,
15 and 30 min, and 1, 2, 4, 9, 24, 48, 96 (day 11 only), 120
(day 11 only), and 168 (day 11 only) h post-dose. A limited
sampling schedule was employed for the remaining patients in
the MTD expansion cohorts.
Plasma concentrations of ixazomib were measured using a
good laboratory practice-validated liquid chromatography/
tandem mass spectrometry (LC/MS/MS) assay with a lower
limit of quantification of 0.5 ng/mL.Whole blood 20S protea-
some activity (expressed as percent proteasome inhibition rel-
ative to baseline) was measured using an established
fluorogenic assay [25], which evaluates the chymotrypsin-
like activity of the β5 subunit of the 20S proteasome, the
primary target of ixazomib.
Tumor biopsies were analyzed for the presence of ixazomib
using a quantified LC/MS/MS methodology validated in xe-
nograft models. Expression of ATF-3 was measured in the
TPEC using an IHC staining assay developed and validated
using preclinical and human primary tumor samples. For this
assay, formalin-fixed, paraffin-embedded tumor biopsy sam-
ples were obtained pre- and post-treatment (at 4–24 h post-
dosing on day 1 or day 4 of cycle 1). Six 5 μm sections from
each tumor sample were then cut (10 μm apart) and stained
with antibody to ATF-3 (Santa Cruz Biotechnology, Inc., sc-
188, lot:K1908) on a Discovery XT autostainer (Ventana
Medical Systems, Inc.). After staining, whole slides were
scanned and analyzed to calculate the percentage ATF-3-
positive area for each section using the Genie™ (Aperio®
ePathology Solutions) pattern recognition tool. The ATF-3-
positive area was measured within the tumor region using
the Positive Pixel Count algorithm, and the percentage ATF-
3-positive area/total tumor area was then calculated for each
section.
Statistical analyses
The safety population included all patients who received ≥1
dose of ixazomib, and the DLT-evaluable population, which
was used for determination of the MTD, comprised patients
who received all cycle 1 doses of ixazomib or experienced a
DLT in cycle 1. The pharmacokinetic and pharmacodynamic
populations included all patients in the dose-escalation cohort
and the first 12 patients treated at the MTD who did not re-
ceive any excluded concomitant medications during the time
of blood sampling, and who had sufficient concentration–time
or effect–time data to permit reliable estimation of
pharmacokinetic/pharmacodynamic parameters. The
response-evaluable population included all patients who re-
ceived ≥1 dose of ixazomib, had measurable disease at base-
line, and had ≥1 post-baseline disease assessment. Approxi-
mately 16 response-evaluable patients were planned to be
evaluated in eachMTD expansion cohort. The binomial prob-
ability calculation showed that if the overall response rate was
10 %, there was approximately an 81 % probability of
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observing ≥1 response and a 49% probability of observing ≥2
responses in 16 patients.
All efficacy and safety data were summarized using de-
scriptive statistics. Pharmacokinetic and pharmacodynamic
parameters were calculated using noncompartmental methods
(WinNonlin software v5.3).
Approximately 16 patients were planned to be enrolled to
the TPEC to estimate ixazomib concentrations in tumors and
target engagement as ATF-3 expression levels. A survey of
human tumors on tissue microarrays, some with multiple tu-
mor samples derived from the same individual, was performed
to evaluate between-subject and within-subject variability in
the ATF-3-positive area. A mixed-effect model using data
from all evaluable pre- and post-dose samples estimated a
within-subject coefficient of variation of 28.33 %. This value
was used to determine the minimum number of sections (n=6)
for pharmacodynamic analysis and the size of the fold change
in ATF-3 that could be detected with 80 % power. Student’s t-
tests on individual patient data were used to determine the
number of patients with a significant fold increase (p<0.05)
in ATF-3 after ixazomib treatment.
Results
Patients
A total of 116 patients were enrolled in this study. Twenty-
three patients were enrolled to the dose-escalation cohort, in-
cluding: one patient each at 0.125, 0.25, and 0.5 mg/m2; seven
patients at 1 mg/m2; four patients at 1.33 mg/m2; six patients
at 1.76 mg/m2; and three patients at 2.34 mg/m2. Seventy-
three patients were enrolled to the MTD expansion cohorts,
including 20 with NSCLC, 22 with head and neck cancer, 20
with soft tissue sarcoma, and 11 with prostate cancer. A total
of 20 patients were enrolled to the TPEC.
Patients’ demographics and baseline disease characteristics
are summarized in Table 1. Patients had received a median of
3 prior lines of therapy (range, 1 to>4) and median time since
primary diagnosis among all patients was 2.5 years.
DLTs and determination of MTD
Of the 23 patients enrolled in the dose-escalation phase, 22
received all doses of ixazomib during cycle 1 and either com-
pleted the cycle or developed a DLT during the cycle; these 22
patients were included in the DLT-evaluable population. One
patient died from progressive thyroid cancer and did not re-
ceive their day 11 dose, and hence was not DLT-evaluable.
Five patients experienced DLTs. One patient treated at the
1.0 mg/m2 dose level reported a DLT of grade 3 pruritic rash.
Ixazomib dosing was held for this patient and, following ad-
ministration of concomitant medication, the rash resolved
within 10 days and the patient continued at a lower dose. At
the 1.76 mg/m2 dose level, one patient reported a DLT of
grade 3 pruritic rash, which persisted despite reducing and
holding the dose of ixazomib; therapy was subsequently
discontinued. The patient was treatedwith hydroxyzine, meth-
ylprednisolone, and diphenhydramine, and the pruritic rash
resolved after 42 days. DLTs reported in three patients treated
at the ixazomib 2.34 mg/m2 dose level were: grade 4 throm-
bocytopenia; grade 3 thrombocytopenia with grade 1 rectal
hemorrhage; and grade 3 acute renal failure (pre-renal azote-
mia associated with nausea, vomiting, diarrhea, and dehydra-
tion). The patient with grade 4 thrombocytopenia was hospi-
talized, and the ixazomib dose was delayed and reduced. The
patient with grade 3 thrombocytopenia with grade 1 rectal
hemorrhage was admitted to hospital and subsequently died
due to progressive disease before the next dose of study drug
was to be administered. The patient with grade 3 acute renal
failure was hospitalized and ixazomib was permanently
discontinued. The MTD of ixazomib was thus determined to
be 1.76 mg/m2 administered on days 1, 4, 8, and 11 of a 21-
day cycle. Patients enrolled to the MTD expansion cohorts
and the TPEC were treated at this dose of ixazomib.
Treatment exposure and safety profile
Patients received a median of 2 treatment cycles (range, 1 to
12) overall, and across all individual cohorts. The maximum
number of cycles received varied by cohort: the maximum
number of cycles was 10, 8, 12, 7, 4, and 4 cycles in the
dose-escalation, NSCLC, head and neck cancer, soft tissue
sarcoma, and prostate cancer cohorts, and the TPEC, respec-
tively. Overall, 23 patients (20 %) received ≥4 cycles; 22 of 99
patients (22 %) treated at the MTD received ≥4 cycles of
therapy. Mean ixazomib dosing compliance (percent total
dose received/total dose expected during time on treatment)
was 97.9 % overall, and was similar across cohorts.
All 116 patients received ≥1 dose of ixazomib and were in-
cluded in the safety population. Of these patients, 115 (99 %)
experienced ≥1 treatment-emergent AE and 104 (90 %) experi-
enced ≥1 drug-related AE (Supplementary Table 1). The most
common drug-related AEs are summarized in Table 2. A total of
84 patients (72 %) had ≥1 treatment-emergent grade ≥3 AE; 66
patients (57 %) had ≥1 drug-related grade ≥3 AE. The most
common drug-related grade ≥3 AEs are shown in Table 3.
Treatment-related skin and subcutaneous (SC) tissue disor-
ders (reported under the MedDRA System Organ class),
which were the most common drug-related AEs overall, were
observed in 61 patients (53 %). These were grade 3 in 18
patients (16 %) and included two of the DLTs. Rash had re-
solved by the end of the study in all but two cases. There was
no grade 4 rash. Duration of rash ranged from 4 to 90 days
(median 15 days). Ten patients received IVor oral corticoste-
roids with or without antihistamine, four patients received IV
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or oral antihistamines alone, and three received topical hydro-
cortisone. Ixazomib was discontinued permanently for one
patient experiencing rash and periorbital edema; this rash re-
solved with concomitant medications.
Thrombocytopenia was the third most frequent drug-
related AE overall (n=52, 45 %) and the most common
drug-related grade ≥3 AE (n=27, 23 %). Median platelet
count appeared to decrease during ixazomib treatment
Table 2 The most common (≥10 % of patients overall) drug-related AEs, overall and within the dose-escalation and expansion cohorts
AE, n (%) Dose-escalation cohort
(n=23)












Skin and SC tissue disordersa 7 (30) 9 (45) 12 (55) 12 (60) 9 (82) 12 (60) 61 (53)
Fatigue 8 (35) 11 (55) 11 (50) 8 (40) 7 (64) 10 (50) 55 (47)
Thrombocytopenia 6 (26) 8 (40) 11 (50) 8 (40) 6 (55) 13 (65) 52 (45)
Nausea 7 (30) 8 (40) 9 (41) 4 (20) 4 (36) 9 (45) 41 (35)
Decreased appetite 7 (30) 6 (30) 5 (23) 5 (25) 4 (36) 11 (55) 38 (33)
Vomiting 5 (22) 8 (40) 7 (32) 6 (30) 2 (18) 8 (40) 36 (31)
Diarrhoea 4 (17) 6 (30) 7 (32) 5 (25) 0 5 (25) 27 (23)
Peripheral neuropathies
NECb
2 (9) 2 (10) 1 (5) 5 (25) 3 (27) 4 (20) 17 (15)
Pyrexia 0 5 (25) 2 (9) 5 (25) 0 4 (20) 16 (14)
Stomatitis 0 3 (15) 3 (14) 4 (20) 2 (18) 2 (10) 14 (12)
Dehydration 1 (4) 4 (20) 5 (23) 0 0 3 (15) 13 (11)
aMedDRASystemOrgan Class – includes rashmaculo-papular (n=20, 17%), rash macular, rash pruritic (each n=15, 13%), rash papular (n=12, 10%),
rash erythematous (n=11, 9 %), rash (n=7, 6 %), pruritus (n=5, 4 %), dermatitis acneiform, dry skin (each n=2, 2 %), alopecia, circumoral edema,
erythema nodosum, exfoliative rash, night sweats, petechiae, skin exfoliation, skin hyperpigmentation, swelling face, and urticaria (each n=1, <1 %).
Patients could have reported >1 AE
bHigh-level term, Peripheral neuropathies NEC – includes neuropathy peripheral and peripheral sensory neuropathy
AE adverse event, H&N head and neck cancer, MTD maximum tolerated dose, NEC not elsewhere classified, NSCLC non-small cell lung cancer, PC
prostate cancer, SC subcutaneous, STS soft tissue sarcoma, TPEC tumor pharmacodynamic expansion cohort
Table 3 The most common (≥3 % of patients overall) drug-related grade ≥3 AEs, overall and within the dose-escalation and expansion cohorts
AE, n (%) Dose-escalation cohort
(n=23)












Thrombocytopenia 5 (22) 2 (10) 7 (32) 3 (15) 3 (27) 7 (35) 27 (23)
Skin and SC tissue disordersa 2 (9) 4 (20) 4 (18) 5 (25) 2 (18) 1 (5) 18 (16)
Fatigue 1 (4) 1 (5) 2 (9) 2 (10) 2 (18) 3 (15) 11 (9)
Dehydration 1 (4) 1 (5) 3 (14) 0 0 2 (10) 7 (6)
Lymphopenia 0 1 (5) 1 (5) 1 (5) 0 3 (15) 6 (5)
Anemia 0 2 (10) 0 0 0 1 (5) 3 (3)
Decreased platelet count 0 2 (10) 0 1 (5) 0 0 3 (3)
Dyspnea 0 1 (5) 1 (5) 0 1 (9) 0 3 (3)
Nausea 1 (4) 0 1 (5) 0 0 1 (5) 3 (3)
Peripheral neuropathies
NECb
1 (4) 0 0 0 1 (9) 1 (5) 3 (3)
Vomiting 1 (4) 0 0 1 (5) 0 1 (5) 3 (3)
aMedDRA System Organ Class – includes rash maculo-papular (n=8, 7 %), rash macular (n=3, 3 %), rash (n=1, <1 %), rash pruritic (n=4, 3 %), rash
erythematous (n=2, 2 %), erythema nodosum, and rash papular (each n=1, <1 %). Patients could have reported >1 AE
bHigh-level term, Peripheral neuropathies NEC – includes neuropathy peripheral and peripheral sensory neuropathy
AE adverse event, H&N head and neck cancer, MTD maximum tolerated dose, NEC not elsewhere classified, NSCLC non-small cell lung cancer, PC
prostate cancer, SC subcutaneous, STS soft tissue sarcoma, TPEC tumor pharmacodynamic expansion cohort
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followed by recovery during the rest period of each cycle (data
not shown). In total, five (4 %) patients required platelet trans-
fusions. Drug-related PNNEC (not elsewhere classified; high-
level term that included neuropathy peripheral and peripheral
sensory neuropathy) was reported in 17 patients (15 %). Most
cases were grade 1 (n=6) or grade 2 (n=8) in intensity. Grade
3 PN NEC occurred in three patients (3 %), all of whom were
receiving the MTD; one had grade 1 neuropathy at screening.
Seventeen patients (15 %) discontinued ixazomib due to
treatment-emergent AEs. In the dose-escalation cohort, one
non-DLT-evaluable patient receiving ixazomib 1.0 mg/m2
discontinued due to disease progression considered unrelated
to ixazomib, one patient receiving 1.76 mg/m2 discontinued
due to the DLT of drug-related pruritic rash, and one patient
receiving 2.34 mg/m2 discontinued due to the DLT of drug-
related acute renal failure. In the NSCLC MTD expansion
cohort, four patients discontinued due to: grade 3 pneumonia
considered unrelated to ixazomib (n=1); drug-related grade 3
pneumonitis (n=1); drug-related grade 3 acute renal failure
and grade 4 thrombocytopenia (n=1); and drug-related grade
2 pruritic rash and grade 2 periorbital edema (n=1). In the
head and neck cancer cohort, five patients discontinued due
to: grade 3 dyspnea (n=1); grade 2 confusional state (n=1);
grade 5 obstructive pneumonia secondary to progressive can-
cer (n=1); grade 5 squamous cell carcinoma (n=1); and grade
2 PN (n=1). Of these five AEs leading to discontinuation,
only grade 3 dyspnea was considered treatment-related. In
the soft tissue sarcoma cohort, two patients discontinued due
to drug-related grade 3 pneumonitis (n=1) and drug-related
grade 3 fatigue (n=1). In the prostate cancer cohort, two pa-
tients discontinued due to drug-related grade 3 ileus (n=1) and
drug-related grade 3 PN (n=1). Lastly, one patient in the
TPEC discontinued due to grade 4 brain metastases consid-
ered unrelated to ixazomib.
Drug-related serious AEs were seen in 32 patients (28 %).
The most common (>2 patients overall) of these events were
thrombocytopenia (n=7, 6 %), nausea, vomiting and dehydra-
tion (each n=4, 3 %), and fatigue (n=3, 3 %). There were
seven on-study deaths. Five patients died due to progressive
disease, one due to obstructive pneumonia secondary to pro-
gressive cancer (as noted above), and one due to acute renal
insufficiency and hypotension. None of the deaths was con-
sidered treatment-related.
Pharmacokinetics and pharmacodynamics
In total, 32 and 36 patients were included in the pharmacoki-
netic and pharmacodynamic (20S blood assay) populations,
respectively. The key pharmacokinetic and pharmacodynamic
parameters determined for these two populations are listed in
Table 4.
Mean plasma concentrations of ixazomib decreased by ap-
proximately 90 % during the initial rapid disposition phase,
which lasted for approximately 8 h (Fig. 1a). The decline in
plasma concentrations was then more gradual during the sub-
sequent slow disposition phase (Fig. 1a), with the terminal
half-life of ixazomib ranging from 3.8 to 7.2 days. Ixazomib
plasma exposure appeared to increase proportionally with in-
creasing ixazomib dose (from 0.5 to 2.34 mg/m2) (Fig. 1b and
Fig. S1). At the 1.76mg/m2MTD, exposures appeared similar
across the expansion cohorts. Accumulation of ixazomib was
approximately 3-fold following the day 11 dose (Fig. 1c and
Fig. S1).
Inhibition of 20S proteasome in whole blood was immedi-
ate (Fig. S2), and maximal inhibition correlated with maxi-
mum plasma concentration. At the MTD of 1.76 mg/m2, an
average maximal inhibition of 20S proteasome activity of
60 % was observed. In general, activity recovered to predose
levels within 24 h following single-dose administration on day
1 (Fig. S2) with the notable exception of patients treated at the
dose level greater than the MTD.
For the drug distribution and ATF-3 IHC analyses, tumor
biopsies were collected from all 20 patients in the TPEC.
Paired pre- and post-dose biopsies of sufficient size were con-
sidered evaluable for pharmacokinetic analysis from 10 pa-
tients; ixazomib was present in all 10 post-dose biopsies ana-
lyzed. Tumor pairs from seven patients (five with colorectal
cancer, one with sarcoma, and one with adrenal cancer) passed
quality control by standard hematoxylin and eosin staining for
tumor content, and were evaluable for ATF-3 IHC. Six of the
seven paired samples showed a statistically significant in-
crease in post-dose ATF-3 levels (p <0.05) (Fig. 2).
Response to treatment
Ninety-two patients received ≥1 cycle of ixazomib treatment,
had measurable disease at baseline, and had ≥1 post-baseline
response assessment, and therefore were included in the
response-evaluable population. Twenty-four patients were
not evaluable for response due to not completing at least 1 cy-
cle of ixazomib treatment (n=12), not having measurable dis-
ease at baseline (n=2), or due to an absence of post-baseline
response assessment (n=10). A partial response was observed
in one patient with head and neck cancer. This response was
achieved after 4 cycles and was maintained for 8 cycles (total
duration, 6.7 months). Stable disease was recorded for 30
patients, including eight with stable disease lasting for ≥4 cy-
cles. Among these eight patients, two were in the dose-
escalation cohort, three were in the NSCLC cohort, one was
in the head and neck cancer cohort and two were in the soft
tissue sarcoma cohort. Measurable tumor reduction was
Fig. 1 aMean plasma concentration–time profiles for ixazomib on day 1
(top panel; n=31) and day 11 (bottom panel; n=26) of dosing, by dose
level, and b geometric mean (% coefficient of variance) Cmax and c AUC
of ixazomib on day 1 and day 11 of dosing, by dose level (n=23)
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observed in two patients with kidney malignancies. One had a
14% reduction in tumor diameter; at the end of the study, their
status was progressive disease with new lesions. The other had
a 22 % reduction in tumor diameter but discontinued from the
study due to grade 3 acute renal failure.
Discussion
This first-in-human phase 1 study met its goal of defining the
MTD and assessing safety of the investigational proteasome
inhibitor ixazomib in patients with a spectrum of solid tumor
types. The MTD for IV ixazomib on a twice-weekly schedule
was established as 1.76 mg/m2. Treatment-related toxicities
included fatigue, thrombocytopenia, gastrointestinal toxic-
ities, and rash. The regimen was generally manageable and
there was a low incidence of PN, which is consistent with
observations from other studies evaluating ixazomib in pa-
tients with hematologic malignancies [26–29]. The pharma-
codynamic investigations demonstrated dose-dependent 20S
proteasome inhibition in blood. Dose limiting toxicity ap-
peared to be associated with a prolonged duration of 20S
proteasome inhibition in patients treated at the dose level
above the MTD, although the number of patients treated is
too small to make any definitive correlation. The study also
provided evidence of target engagement in tumor tissue dur-
ing treatment through the increase in ATF-3 expression in
post-dose tumor samples. ATF-3 is a marker of unfolded pro-
tein response/endoplasmic reticulum stress, which is upregu-
lated in response to proteasome inhibition [30–32]. The ATF-
3 data therefore represent the first pharmacodynamic evidence
of proteasome pathway inhibition in solid tumors following
ixazomib dosing. However, despite evidence of proteasome
inhibition and pathway effects, IV ixazomib demonstrated on-
ly limited antitumor activity in these study patients with ad-
vanced non-hematologic malignancies. This is consistent with
reports that pharmacological response is not a guarantee of a
significant clinical response [33, 34]. Measurement of drug
effect at the tumor site provides direct evidence that the drug
has reached its target. ATF-3 upregulation has been widely
observed in preclinical experiments conducted in more than
15 xenograft tumors treated with ixazomib; however, not all
these xenograft models show tumor growth inhibition in re-
sponse to ixazomib, and therefore it serves as a pharmacody-
namic marker and not a predictor of efficacy even in preclin-
ical models (data not shown).
The five DLTs reported with IV twice-weekly ixazomib
included two cases of grade 3 pruritic rash reported at or
below the MTD, grade 3 and 4 thrombocytopenia, and grade
3 acute renal failure seen at 2.34 mg/m2, the dose level above
the MTD. The overall toxicity profile observed in this study
was similar to those previously reported in other clinical stud-
ies of oral ixazomib in MM and light-chain amyloidosis, and
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of IV ixazomib in lymphoma (in which rash and hematologic
AEs were the most common DLTs) [26–29].
Overall, AEs were manageable; common all-grade and
grade ≥3 toxicities included fatigue, thrombocytopenia, gastro-
intestinal toxicities, and skin toxicities, especially rash. Gener-
ally, AEs of rash were manageable with antihistamines or low-
dose topical/oral corticosteroids (if they did not resolve sponta-
neously during the rest week of therapy), and were reversible in
the majority of cases, while thrombocytopenia appeared to be
cyclical and reversible, as reported in other studies of ixazomib
[27, 29]. Gastrointestinal toxicities tended to resolve with ap-
propriate supportive therapy. Comparable to other studies of
single-agent ixazomib [26–29], there was a low rate of
treatment-related PN, including 3 % grade ≥3 events, all at
the MTD. This is in contrast to the rates seen with bortezomib,
where PN is amore common toxicity [35], but it is similar to the
low rates reported for carfilzomib [36, 37]. It should be noted,
however, that patients received a median of 2 cycles of treat-
ment, and only one-fifth of patients received 4 cycles or more.
Therefore, this treatment exposure may not have permitted a
comprehensive understanding of the safety and tolerability pro-
file of IV ixazomib in patients with solid tumors.
This paper describes for the first time the pharmacokinetic
profile of ixazomib in patients with solid tumors. The phar-
macokinetic analysis showed that ixazomib plasma concen-
trations decreased by approximately 90 % within the first 8 h
post-dose and the terminal half-life ranged from3.8 to 7.2 days
following multiple dosing, similar to results seen in patients
with MM [29]. Additionally, across the full range of doses
tested (0.5 to 2.34 mg/m2), plasma exposure appeared to in-
crease proportionally with increasing dose, and this did not
differ markedly among patients with different tumor types.
Current studies are investigating the pharmacokinetic profile
of ixazomib following oral dosing, which has been selected as
the route of administration for further clinical development of
ixazomib in patients with hematologic malignancies, where
the drug shows substantial clinical activity [26–29].
The lack of clinical activity in the present study is compa-
rable to observations from bortezomib and carfilzomib studies
in advanced solid tumors [7–13, 38]. At the MTD of 1.76 mg/
m2, only one patient with head and neck cancer achieved a
partial response with ixazomib treatment. The lack of efficacy
may be due to suboptimal duration of target inhibition at tol-
erable doses, but clinical activity can depend on many factors
in addition to target inhibition, such as treatment duration,
toxicity, and patient selection. A better understanding of addi-
tional response determinants including degree and duration of
Fig. 2 a Activating transcription factor-3 (ATF-3) levels in seven paired
pre- and post-dose tumor biopsies from patients in the tumor
pharmacodynamic expansion cohort, b fold-change in ATF-3 levels
post- versus pre-dose and statistical significance (t-test) by patient, and
c ATF-3 staining of pre- and post-dose tumor samples from one patient
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target inhibition is needed to improve outcomes in clinical
studies investigating proteasome inhibitors. In conclusion, this
study determined the safety profile, MTD, and pharmacoki-
netics and blood pharmacodynamics of IV ixazomib in pa-
tients with non-hematologic malignancies. Despite the dem-
onstrated drug distribution and downstream effects of protea-
some inhibition in solid tumor tissue, limited antitumor activ-
ity was observed in predefined tumor types, although it is of
interest that one heavily pretreated patient with head and neck
carcinoma experienced a durable response. Weekly oral
ixazomib is currently being investigated in ongoing phase 3
trials in MM and primary systemic AL amyloidosis.
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